Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46.16 USD | +1.10% | +2.60% | +14.68% |
May. 13 | Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating | MT |
May. 10 | Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 44.75M | Capitalization | 1.68B |
---|---|---|---|---|---|
Net income 2024 * | -96M | Net income 2025 * | -61M | EV / Sales 2024 * | - |
Net cash position 2024 * | 238M | Net cash position 2025 * | 151M | EV / Sales 2025 * | 34.2 x |
P/E ratio 2024 * |
-18.2
x | P/E ratio 2025 * |
-29.5
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.86% |
Latest transcript on Soleno Therapeutics, Inc.
1 day | +1.10% | ||
1 week | +2.60% | ||
Current month | +3.36% | ||
1 month | +21.79% | ||
3 months | -2.45% | ||
6 months | +79.12% | ||
Current year | +14.68% |
Managers | Title | Age | Since |
---|---|---|---|
Anish Bhatnagar
CEO | Chief Executive Officer | 56 | 05-12-31 |
James Mackaness
DFI | Director of Finance/CFO | 60 | 19-11-13 |
Ernest Mario
CHM | Chairman | 85 | 07-08-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ernest Mario
CHM | Chairman | 85 | 07-08-02 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 19-04-25 |
Bill Harris
BRD | Director/Board Member | 65 | 14-06-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 46.16 | +1.10% | 334,444 |
24-05-16 | 45.66 | +1.00% | 214,555 |
24-05-15 | 45.21 | +3.93% | 531,722 |
24-05-14 | 43.5 | +1.64% | 219,419 |
24-05-13 | 42.8 | -4.87% | 429,620 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.68% | 1.68B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- SLNO Stock